Research programme: ER stress response modulators - Aravive Biologics

Drug Profile

Research programme: ER stress response modulators - Aravive Biologics

Alternative Names: 2-series; 4-series ER stress

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ruga Corporation
  • Developer Aravive Biologics
  • Class
  • Mechanism of Action Cell physiology modulators; Protein folding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Multiple-myeloma in USA
  • 22 May 2012 Early research in Multiple myeloma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top